PMID- 31277179
OWN - NLM
STAT- MEDLINE
DCOM- 20190717
LR  - 20231012
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 27
DP  - 2019 Jul
TI  - Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with 
      cancer: Protocol for an overview of systematic reviews with meta-analyses.
PG  - e16324
LID - 10.1097/MD.0000000000016324 [doi]
LID - e16324
AB  - BACKGROUND: Anti-programmed cell death 1 (PD-1) and anti-programmed cell death 
      ligand 1 (PD-L1) drugs treatment-related adverse events (AEs) are not uniform 
      based on current study for patients with cancer. The study aimed to provide a 
      complete toxicity profile and toxicity spectrum for anti-PD-1 and anti-PD-L1 
      drugs. METHODS: All systematic reviews (SRs) with meta-analyses (MAs) relate to 
      the anti-PD-1 and anti-PD-L1 drugs and SRs will be searched in the database of 
      PubMed, Embase, Cochrane Library, and Web of Science from inception to February 
      2019. Eligible publications must have reported site, organ, or system level data 
      on treatment-related AEs. The following will extract from each SRs: first author, 
      year of publication, country of origin, number of origin study, number of 
      patients enrolled, participant characteristics, duration of cancer diagnosis, 
      cancer types, detailed description of treatment, and occurrence of AEs. Preferred 
      Reporting Items for Systematic Review and Meta-analysis (PRISMA) and A 
      Measurements Tool to Assess Systematic Reviews 2 (AMSTAR-2) will be used to 
      assess the reporting and methodological quality of SRs/MAs. The characteristics 
      of the included SRs/MAs and their quality will descriptively summarized using 
      systematically structured tables. A network meta-analysis (NMAs) approach versus 
      a narrative synthesis will be used to examine data synthesis considered. Odds 
      ratios and 95% credibility intervals will be used as summary statistics. Evidence 
      mapping (EM) method will to present the evidence landscape related to anti-PD-1 
      and anti-PD-L1 drugs treatment-related AEs for patients with cancer. DISCUSSION: 
      The results of the overview will be submitted to a peer-reviewed journal for 
      publication. ETHICS AND DISSEMINATION: Because this study is not a clinical 
      study, and we will search and evaluate only existing sources of literature. So, 
      ethical approval is not required.
FAU - Li, Jing
AU  - Li J
AD  - Gansu Provincial Cancer Hospital.
FAU - Liu, Ming
AU  - Liu M
AD  - School of Basic Medical Sciences, Lanzhou University.
FAU - Wang, JianShu
AU  - Wang J
AD  - Gansu Provincial Cancer Hospital.
FAU - Liu, Zhao
AU  - Liu Z
AD  - Gansu Provincial Cancer Hospital.
FAU - Xue, JinXu
AU  - Xue J
AD  - Gansu Provincial Cancer Hospital.
FAU - Wang, JianCheng
AU  - Wang J
AD  - Gansu Provincial Hospital.
AD  - Hospital Management Research Center, Lanzhou University.
FAU - Jia, JunHai
AU  - Jia J
AD  - Gansu Provincial Hospital Rehabilitation Center, Lanzhou, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Antineoplastic Agents, Immunological/*adverse effects
MH  - B7-H1 Antigen/*immunology
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Neoplasms/*drug therapy
MH  - Programmed Cell Death 1 Receptor/*immunology
MH  - Systematic Reviews as Topic
PMC - PMC6635244
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2019/07/07 06:00
MHDA- 2019/07/18 06:00
PMCR- 2019/07/05
CRDT- 2019/07/07 06:00
PHST- 2019/07/07 06:00 [entrez]
PHST- 2019/07/07 06:00 [pubmed]
PHST- 2019/07/18 06:00 [medline]
PHST- 2019/07/05 00:00 [pmc-release]
AID - 00005792-201907050-00094 [pii]
AID - MD-D-19-04630 [pii]
AID - 10.1097/MD.0000000000016324 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Jul;98(27):e16324. doi: 10.1097/MD.0000000000016324.